{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462263110
| IUPAC_name = (13-Ethyl-17-ethynyl-3-hydroxyimino- 1,2,6,7,8,9,10,11,12,14,15,16- dodecahydrocyclopenta[a]phenanthren-17-yl) acetate
| image = Norgestimate.svg
| width = 250
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|norgestimate}}
| MedlinePlus = a601050
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 12–30 hours
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7091
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 35189-28-7
| ATC_prefix = G03
| ATC_suffix = AA11
| ATC_supplemental = {{ATC|G03|FA13}} (only combinations with [[estrogen]]s)
| PubChem = 6540478
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00957
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5022837
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C291HFX4DY
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05209
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50815
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200934
| synonyms = ORF-10131; Norgestrel acetate oxime; Norgestrel 17β-acetate 3-oxime; 17α-Ethynyl-18-methyl-19-nortestosterone 3-oxime 17β-acetate; 17α-Ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime 17β-acetate

<!--Chemical data-->
| C=23 | H=31 | N=1 | O=3
| molecular_weight = 369.497 g/mol
| smiles = O=C(O[C@@]2(C#C)CC[C@H]1[C@H]4[C@H](CC[C@@]12CC)[C@@H]3/C(=C\C(=N\O)CC3)CC4)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KIQQMECNKUGGKA-NMYWJIRASA-N
}}
{{Distinguish|norgestomet}}

'''Norgestimate''' (brand names '''Ortho-Cyclen''', '''Ortho Tri-Cyclen''', '''Previfem''', '''Sprintec''', '''Prefest''', others) is a [[progestin]] that is used in combination with [[ethinylestradiol]] as an [[oral contraceptive]] and in combination with [[estradiol]] in [[menopause|menopausal]] [[hormone replacement therapy (menopause)|hormone replacement therapy]].<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1316|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=1316–}}</ref> It is a [[prodrug]], mainly of [[norelgestromin]], but also of [[levonorgestrel]] in small amounts.<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1316|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=1316–}}</ref><ref name="FalconeHurd2007">{{cite book|author1=Tommaso Falcone|author2=William W. Hurd|title=Clinical Reproductive Medicine and Surgery|url=https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA389|year=2007|publisher=Elsevier Health Sciences|isbn=0-323-03309-1|pages=389–}}</ref>

==Pharmacology==
Norgestimate, unlike related progestins such as levonorgestrel, shows high [[binding selectivity|selectivity]] for the [[progesterone receptor]] (PR) and little [[androgen]]ic activity.<ref name="LemkeWilliams2008" /><ref name="pmid2571595">{{cite journal | vauthors = Chapdelaine A, Desmarais JL, Derman RJ | title = Clinical evidence of the minimal androgenic activity of norgestimate | journal = Int. J. Fertil. | volume = 34 | issue = 5 | pages = 347–52 | year = 1989 | pmid = 2571595 | doi = | url = }}</ref> Moreover, norgestimate and its main [[active metabolite]] norelgestromin do not bind to or occupy [[sex hormone-binding globulin]] (SHBG).<ref name="LemkeWilliams2008" /> In accordance, [[clinical trial]]s of norgestimate have observed minimal androgenic [[side effect]]s.<ref name="pmid2571595" />

===Androgenic activity===
The [[relative binding affinity]] of norgestimate and its metabolite norelgestromin for the rat [[prostate gland|prostatic]] [[androgen receptor]] (AR) are 0.3% and 1.3% of those of [[dihydrotestosterone]] (DHT), respectively, whereas the respective values for [[levonorgestrel]] and [[gestodene]] are 22.0% and 15.4%.<ref name="pmid1415445">{{cite journal | vauthors = Phillips A, Hahn DW, McGuire JL | title = Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity | journal = Am. J. Obstet. Gynecol. | volume = 167 | issue = 4 Pt 2 | pages = 1191–6 | year = 1992 | pmid = 1415445 | doi = | url = }}</ref> Moreover, the ratios of AR to PR binding are 219 for norgestimate and 48 for its metabolite norelgestromin, whereas the ratios of [[progesterone]], levonorgestrel, and gestodene are 93, 11, and 28, respectively.<ref name="pmid1415445" />

[[Estrogen]]s increase and androgens inhibit hepatic production of SHBG and by extension circulating SHBG levels.<ref name="pmid1415445" /> Clinical studies have found that norgestimate does not appreciably inhibit the increase in SHBG levels produced by ethinylestradiol, and this is in accordance with preclinical research and the notion that norgestimate is minimally androgenic.<ref name="pmid1415445" /> In addition, norgestimate and norelgestromin show virtually no affinity for SHBG, unlike levonorgestrel and gestodene (which have 87% and 202% of the relative binding affinity of [[testosterone]] for SHBG, respectively) but similarly to progesterone.<ref name="pmid1415445" />

==Pharmacokinetics==
Norgestimate acts as a [[prodrug]] to [[norelgestromin]] (17β-deacetylnorgestimate or levonorgestrel 3-oxime), the primary [[active metabolite]], and to a lesser extent to [[levonorgestrel]] (~22% of an administered dose; [[deacetylation]] of norgestimate occurs in the [[intestine]]s and the [[liver]]), as well as to [[levonorgestrel 17β-acetate]] in very small quantities.<ref name="LemkeWilliams2008" /><ref name="HumansOrganization2007">{{cite book|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=World Health Organization|author3=International Agency for Research on Cancer|title=Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy|url=https://books.google.com/books?id=aGDU5xibtNgC&pg=PA151|year=2007|publisher=World Health Organization|isbn=978-92-832-1291-1|pages=150–151}}</ref><ref name="pmid12215716">{{cite journal | vauthors = Stanczyk FZ | title = Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception | journal = Rev Endocr Metab Disord | volume = 3 | issue = 3 | pages = 211–24 | year = 2002 | pmid = 12215716 | doi = 10.1023/A:1020072325818| url = }}</ref>

==Chemistry==
{{See also|List of steroidal progestogens|Progestogen ester}}

Norgestimate, also known as '''17α-ethynyl-18-methyl-19-nortestosterone 3-oxime 17β-acetate''' or as '''17α-ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime 17β-acetate''', is a [[synthetic compound|synthetic]] [[estrane]] [[steroid]] and a [[chemical derivative|derivative]] of [[testosterone]].<ref name="Elks2014" /><ref name="Drugs.com" /> It is more specifically a derivative of [[norethisterone]] (17α-ethynyl-19-nortestosterone) and is a member of the [[gonane]] (18-methylestrane) subgroup of the [[19-nortestosterone]] family of progestins.<ref name="StraussBarbieri2009">{{cite book|author1=Jerome Frank Strauss|author2=Robert L. Barbieri|title=Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management|url=https://books.google.com/books?id=NudwnhxY8kYC&pg=PA878|year=2009|publisher=Elsevier Health Sciences|isbn=1-4160-4907-X|pages=878–}}</ref> Norgestimate is the C3 [[oxime]] and C17β [[acetate]] [[ester]] of [[levonorgestrel]] and is also known as '''levonorgestrel acetate oxime'''.<ref name="Skouby1997">{{cite book|author=Sven O. Skouby|title=Clinical Perspectives on a New Gestodene Oral Contraceptive Containing 20μg of Ethinylestradiol|url=https://books.google.com/books?id=IYj54F5zvM4C&pg=PA11|date=15 July 1997|publisher=CRC Press|isbn=978-1-85070-786-8|pages=11–}}</ref>

==History==
Norgestimate was introduced in 1986.<ref name="RunnebaumRabe2012">{{cite book|author1=Benno Clemens Runnebaum|author2=Thomas Rabe|author3=Ludwig Kiesel|title=Female Contraception: Update and Trends|url=https://books.google.com/books?id=LtT6CAAAQBAJ&pg=PA13|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-73790-9|pages=13–}}</ref>

==Society and culture==

===Generic name===
''Norgestimate'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|USP|United States Pharmacopeia}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|DCF|Dénomination Commune Française}}.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA887|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=887–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/norgestimate.html</ref>

==See also==
* [[Norethisterone acetate oxime]]

==References==
{{Reflist|2}}


{{Progestogens and antiprogestogens}}
{{Androgens and antiandrogens}}
{{Progesterone receptor modulators}}
{{Androgen receptor modulators}}

[[Category:Acetate esters]]
[[Category:Alkynes]]
[[Category:Androgens and anabolic steroids]]
[[Category:Estranes]]
[[Category:Oximes]]
[[Category:Prodrugs]]
[[Category:Progestogen esters]]
[[Category:Progestogens]]